Status:

COMPLETED

Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus

Lead Sponsor:

Sun Pharmaceutical Industries Limited

Conditions:

Type 2 Diabetes Mellitus

Eligibility:

All Genders

20+ years

Phase:

PHASE3

Brief Summary

SPIL1033 resembles a gut hormone, which increases the insulin secretion, thus helps in reducing blood glucose levels. The purpose of study is to establish safety and efficacy of SPIL1033

Detailed Description

SPIL1033 is subcutaneous injection is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus. In this study, efficacy and safety of SPIL1033 will be eva...

Eligibility Criteria

Inclusion

  • Male and female subjects 20 years of age and older.
  • Established clinical diagnosis of type 2 diabetes mellitus treated with diet and exercise or anti-diabetic agents as monotherapy or combination therapy.
  • Weight stable: their weight should not have varied more than 10% of screening visit weight, within 6 months prior to screening visit.
  • Women of child bearing potential practicing an acceptable method of birth control as judged by the investigator(s); with a negative urine pregnancy test.
  • Willing to participate and give written informed consent.

Exclusion

  • Previous exposure to exenatide (anti-exenatide antibodies at screening) or a glucagon-like peptide (GLP-1) analogue.
  • Used drugs for weight loss (for example, orlistat, sibutramine, phenylpropanolamine, rimonabant, or similar over-the-counter medications) within 3 months of screening.
  • Received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of trial entry.
  • Severe renal impairment (creatinine clearance \<30 ml/min) or end stage renal disease.

Key Trial Info

Start Date :

March 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 4 2015

Estimated Enrollment :

360 Patients enrolled

Trial Details

Trial ID

NCT01406717

Start Date

March 1 2013

End Date

November 4 2015

Last Update

August 11 2020

Active Locations (34)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 9 (34 locations)

1

SPIL Site 22

Hyderabad, Andhra Pradesh, India

2

SPIL Site 25

Hyderabad, Andhra Pradesh, India

3

SPIL Site 26

Hyderabad, Andhra Pradesh, India

4

SPIL Site 23

Visakhapatnam, Andhra Pradesh, India